ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 23.89 percent. This is a 12.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $225.000 thousand which beat the analyst consensus estimate of $83.333 thousand by 170.00 percent.